NVO at 10x Earnings: Wall Street's Biggest Blind Spot

The FDA's approval of Wegovy HD on March 19 was not a minor label expansion. This is the first GLP-1 drug approved under the agency's accelerated review pathway — a signal that regulators view the obesity epidemic as urgent enough to fast-track treatments. The 7.2mg dose produced 20.7% average body weight reduction over 72 weeks. Nearly a third of trial participants lost more than 25% of their body weight.

Those numbers matter because they close the efficacy gap with Eli Lilly's tirzepatide, which has been the primary competitive threat driving NVO's multiple compression. The bear case rested on the assumption that Novo's pipeline could not match Lilly's next-generation results. Wegovy HD directly challenges that assumption, and it launches in April 2026 — weeks from now.

The market has not priced this in. At 10.35x trailing earnings, NVO trades as though Wegovy HD does not exist, as though the FDA approval never happened, as though the April launch is irrelevant. Analysts expect quarterly EPS in the $5.80 to $6.56 range through fiscal year 2027. If Wegovy HD captures even modest incremental share in the $100 billion-plus GLP-1 market, those estimates look conservative.

Novo Nordisk's financial profile belongs in a different conversation than its current valuation suggests. Gross margins above 80% are the province of software companies and luxury goods makers. A 40.3% operating margin in Q4 2025 reflects pricing power, manufacturing efficiency, and a product portfolio that customers — patients and healthcare systems alike — cannot easily replace.

Full-year 2025 EPS totaled approximately $23, derived from quarterly prints of $6.54, $5.96, $4.50, and $6.04. The Q3 dip to $4.50 — driven by CagriSema-related charges and the price cuts — spooked the market. But Q4's rebound to $6.04 demonstrated that the earnings power is intact. Net margins of 34.0% in Q4 confirm this is not a company squeezing profits through financial engineering. The cash generation is real, recurring, and growing.

For context, a $162 billion market cap against roughly $23 in annual EPS across 4.44 billion shares outstanding means Novo is generating earnings at a pace that most companies at this valuation cannot match. The 50-day moving average sits at $48.31 and the 200-day at $54.90 — both far above the current price, suggesting the recent plunge has overshot even the trend that bears established.

The compounding pharmacy threat is fading. Novo has filed approximately 130 lawsuits against compounders, and the FDA has signalled it will restrict GLP-1 compounding now that the official shortage has ended. The Hims & Hers saga — where a $49 compounded semaglutide pill lasted exactly two days before regulatory and legal pressure killed it — demonstrated that the patent fortress holds. Hims has since pivoted to a distribution deal with Novo rather than competing against it. When your competitor joins your distribution network, that is not a threat. That is a moat.

China represents another underappreciated catalyst. Signals from the vice commerce minister regarding market expansion suggest Novo is positioning for regulatory approval in the world's largest untapped GLP-1 market. China's obesity rates are climbing rapidly, and no dominant GLP-1 player has established the kind of foothold that Novo could capture with first-mover advantage.

The intellectual property position deserves attention too. Semaglutide patents extend well into the 2030s, and the 130-lawsuit campaign against compounders is not defensive posturing — it is a systematic effort to seal the moat before generic competition becomes a realistic threat. Every compounder that settles or loses reinforces the legal precedent. Every FDA enforcement action narrows the grey market. The window for knockoff semaglutide is closing, not opening.

The competitive picture is not Novo versus the world. It is Novo and Lilly splitting a market that Goldman Sachs estimates will reach $130 billion by 2030. In a duopoly with that kind of total addressable market, both companies win. Pricing NVO at 10x earnings assumes it loses — and the Q4 numbers say otherwise.

The earnings announcement on May 6, 2026 is the next inflection point. If Q1 2026 results reflect early Wegovy HD launch momentum, the re-rating could be violent. Stocks do not move from 10x to 15x gradually — they gap up on the open when the narrative flips.

Consider the asymmetry. At $36.53, NVO is priced for permanent earnings decline. If earnings merely hold steady at $23 per share and the multiple re-rates to a still-modest 15x, the stock trades at $345 on a pre-split equivalent basis — roughly $69 per share adjusted. That is 89% upside from current levels, requiring nothing more than the market acknowledging that the business has not, in fact, collapsed.

If Wegovy HD drives earnings growth — which the forward estimates of $5.80 to $6.56 per quarter suggest is the base case — the upside expands further. At the midpoint of analyst estimates, FY2026 EPS would land around $24.50, meaning the forward P/E is closer to 9x. A company growing EPS with 80% gross margins and a new product launch does not deserve a lower multiple than the S&P 500 average.

The risk-reward calculus is lopsided. Downside from $36.53 to the 52-week low of $35.85 is 68 cents — less than 2%. Upside to the 200-day moving average of $54.90 is 50%. Upside to a 15x multiple on current earnings is 89%. The market is offering a near-asymmetric bet on the world's largest obesity-drug company at a price that assumes its best days are behind it. The current pricing reflects maximum pessimism at the exact moment the fundamental picture is improving. That is the definition of a contrarian opportunity.